

Cancer Survivorship Committee

Leadership

Co-Chairs: Melinda Irwin, PhD, MPH
 Halle Moore, MD
 Statistician: Katherine Guthrie, Ph.D
 Executive Officer: Virginia Sun Ph.D, RN
 Patient Advocate: Lee Jones

Time/Location

Thursday, May 11, 2023 11:30 am - 1:30 pm
 Room: Garden Room (Atrium Lobby Level)

Agenda

Welcome & Introductions: Melinda Irwin and Halle Moore

Survivorship Presentation: Shelley Fuld Nasso, CEO National Coalition for Cancer Survivorship

Discussion

Patient Advocate Update: Lee Jones

New Ideas

Studies/Concepts

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer." Justin Floyd, D.O. and Monika Leja, M.D.

S2204, "Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers." Dan Raz and Virginia Sun.

S2013 I-CHECKIT, "Immune CHECKpoint Inhibitory Toxicity analysis." Krishna Gunturu. Concept approved (Also in QOL and Symptom Control Committee)

Impact of immune checkpoint inhibitors on gonadal reserve: a longitudinal analysis of biospecimens from S1404: Katy Tsai

SWOG 0816 a secondary analysis of predictors of muscle wasting, Vickie Baracos

Randomized, phase II trial of vortioxetine for the reduction of ADT-induced cognitive impairment. Chethan Ramamurthy, MD and Ian M. Thompson II, MD

ALTE2131, "Gonadotropin-Releasing Hormone Analogs (GnRHa) and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer." COG led, SWOG champion is Halle Moore

Use of Continuous Glucose Monitoring to Improve Glycemic Safety and Reduce Infectious Complications in AYA ALL patients: GOG led (Allison Grimes), SWOG champion is Stephanie Tsai

Liaison Updates/Other Business

Active Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated 9/15/17.

Closed Study

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. Krouse, Denevee, and Sun. Activated: 3/9/15; Permanently Closed: 5/15/20.

Cancer Survivorship Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	S1501	EA9131
Ascension Providence Hospitals - Southfield	4	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	6	1
Bay Area Tumor Institute NCORP	2	-
CWRU Case Comprehensive Cancer Center LAPS	14	-
Cancer Research for the Ozarks NCORP	9	-
City of Hope Comprehensive Cancer Center	44	-
Columbia University Minority Underserved NCORP	2	-
CommonSpirit Health Research Institute	1	-
Fred Hutchinson Cancer Research Center LAPS	4	-
Georgia Cares Minority Underserved NCORP	-	1
Georgia NCI Community Oncology Research Program	12	-
Gulf South Minority Underserved NCORP	4	-
Heartland Cancer Research NCORP	19	-
Henry Ford Hospital	2	-
Kaiser Permanente NCI Community Oncology Research Program	1	60
King Faisal Specialist Hospital and Research Centre	3	-
Lahey Hospital and Medical Center	6	-
Loyola University Medical Center	8	-
Medical University of South Carolina Minority Underserved NCORP	1	-
Michigan Cancer Research Consortium NCORP	3	-
Moffitt Cancer Center	18	-
Montana Cancer Consortium NCORP	1	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
National Cancer Center-Korea	1	-
New Mexico Minority Underserved NCORP	6	-
Oregon Health and Science University	1	-
UC Davis Comprehensive Cancer Center LAPS	2	-
USC Norris Comprehensive Cancer Center LAPS	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-
University of Michigan Comprehensive Cancer Center LAPS	10	-
Wayne State University - Karmanos Cancer Institute LAPS	6	-
ALLIANCE	22	-
ECOG-ACRIN	39	-
NRG	22	-
Total	286	62